DE602006019119D1 - Verbindungen mit aktivität am m1-rezeptor und ihre verwendung in der medizin - Google Patents

Verbindungen mit aktivität am m1-rezeptor und ihre verwendung in der medizin

Info

Publication number
DE602006019119D1
DE602006019119D1 DE602006019119T DE602006019119T DE602006019119D1 DE 602006019119 D1 DE602006019119 D1 DE 602006019119D1 DE 602006019119 T DE602006019119 T DE 602006019119T DE 602006019119 T DE602006019119 T DE 602006019119T DE 602006019119 D1 DE602006019119 D1 DE 602006019119D1
Authority
DE
Germany
Prior art keywords
receptor
medicine
activity
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006019119T
Other languages
German (de)
English (en)
Inventor
Brian Budzik
David Gwyn Cooper
Ian Thomson Forbes
Vincenzo Garzya
Jian Jin
Dongchuan Shi
Paul William Smith
Graham Walker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0519950.0A external-priority patent/GB0519950D0/en
Priority claimed from GB0602040A external-priority patent/GB0602040D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of DE602006019119D1 publication Critical patent/DE602006019119D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
DE602006019119T 2005-09-30 2006-09-27 Verbindungen mit aktivität am m1-rezeptor und ihre verwendung in der medizin Active DE602006019119D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0519950.0A GB0519950D0 (en) 2005-09-30 2005-09-30 Compounds
GB0602040A GB0602040D0 (en) 2006-02-01 2006-02-01 Compounds
PCT/GB2006/003590 WO2007036715A2 (en) 2005-09-30 2006-09-27 Compounds which have activity at m1 receptor and their uses in medicine

Publications (1)

Publication Number Publication Date
DE602006019119D1 true DE602006019119D1 (de) 2011-02-03

Family

ID=37598231

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006019119T Active DE602006019119D1 (de) 2005-09-30 2006-09-27 Verbindungen mit aktivität am m1-rezeptor und ihre verwendung in der medizin

Country Status (24)

Country Link
US (2) US8283364B2 (enExample)
EP (1) EP1943230B1 (enExample)
JP (1) JP5209480B2 (enExample)
KR (2) KR20130091791A (enExample)
CN (1) CN101321736B (enExample)
AR (1) AR056103A1 (enExample)
AT (1) ATE492537T1 (enExample)
AU (1) AU2006296369B2 (enExample)
BR (1) BRPI0616609A2 (enExample)
CA (1) CA2624504C (enExample)
CR (1) CR9904A (enExample)
DE (1) DE602006019119D1 (enExample)
EA (1) EA016286B1 (enExample)
IL (1) IL190219A (enExample)
JO (1) JO2634B1 (enExample)
MA (1) MA29849B1 (enExample)
MY (1) MY148504A (enExample)
NO (1) NO20081945L (enExample)
NZ (1) NZ566508A (enExample)
PE (1) PE20070490A1 (enExample)
TW (1) TWI389905B (enExample)
UA (1) UA101299C2 (enExample)
WO (1) WO2007036715A2 (enExample)
ZA (1) ZA200802167B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5209481B2 (ja) 2005-09-30 2013-06-12 グラクソ グループ リミテッド Ｍ１受容体にて活性を有する化合物および医薬におけるそれらの使用
JP5209480B2 (ja) 2005-09-30 2013-06-12 グラクソ グループ リミテッド Ｍ１受容体にて活性を有する化合物および医薬におけるそれらの使用
JP5209479B2 (ja) * 2005-09-30 2013-06-12 グラクソ グループ リミテッド Ｍ１受容体にて活性を有するベンゾイミダゾロン類
US7766829B2 (en) * 2005-11-04 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
GB0605785D0 (en) * 2006-03-22 2006-05-03 Glaxo Group Ltd Compounds
GB0706170D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706174D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706164D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706165D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0718415D0 (en) * 2007-09-20 2007-10-31 Glaxo Group Ltd Compounds
WO2009124882A1 (en) * 2008-04-09 2009-10-15 H. Lundbeck A/S Novel piperidinyl-1,3-dihydro-benzoimidazol-2-ones as m1 agonists
GB0817982D0 (en) 2008-10-01 2008-11-05 Glaxo Group Ltd Compounds
CA2966594A1 (en) * 2014-11-03 2016-05-12 William Beaumont Hospital Method for treating underactive bladder syndrome
CA2984305C (en) * 2015-04-29 2021-12-28 Janssen Pharmaceutica Nv Indolone compounds and their use as ampa receptor modulators
HUE053943T2 (hu) 2015-04-29 2021-08-30 Janssen Pharmaceutica Nv Azabenzimidazolok és ampa receptor modulátorokként való alkalmazásuk
US20180250270A1 (en) 2015-09-11 2018-09-06 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
CN107673994A (zh) * 2017-04-27 2018-02-09 联化科技股份有限公司 一种芳基甲烷类化合物的制备方法
CN107739342B (zh) * 2017-11-29 2020-01-10 华南理工大学 一种一步合成5-二芳氨基苯并咪唑酮衍生物的方法
CN117049938B (zh) * 2023-06-20 2024-06-14 山东轩德医药科技有限公司 一种6-溴-2,3-二氟甲苯的制备方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3161645A (en) * 1962-12-18 1964-12-15 Res Lab Dr C Janssen N V 1-(1-aroylpropyl-4-piperidyl)-2-benzimidazolinones and related compounds
US3989707A (en) * 1974-06-21 1976-11-02 Janssen Pharmaceutica N.V. Benzimidazolinone derivatives
US4292321A (en) * 1979-05-24 1981-09-29 Warner-Lambert Company 1,3,8-Triazaspirodecane-4-ones, pharmaceutical compositions thereof and method of use thereof
DE3124366A1 (de) * 1981-06-20 1982-12-30 Hoechst Ag, 6000 Frankfurt N-oxacyclyl-alkylpiperidin-derivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische praeparate und deren verwendung
DE4040300A1 (de) 1990-12-17 1992-07-02 Leifeld Gmbh & Co Drueckmaschine mit wenigstens einem rollenhalter
JP3916093B2 (ja) * 1993-09-17 2007-05-16 杏林製薬株式会社 光学活性イミダゾリジノン誘導体とその製造方法
JP2002515008A (ja) * 1994-10-27 2002-05-21 メルク エンド カンパニー インコーポレーテッド ムスカリン・アンタゴニスト
US5574044A (en) * 1994-10-27 1996-11-12 Merck & Co., Inc. Muscarine antagonists
US5691323A (en) * 1995-05-12 1997-11-25 Merck & Co., Inc. Muscarine antagonists
WO1997016186A1 (en) 1995-10-31 1997-05-09 Merck & Co., Inc. Muscarine agonists
US5718912A (en) * 1996-10-28 1998-02-17 Merck & Co., Inc. Muscarine agonists
US5977134A (en) * 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6465484B1 (en) * 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
WO1999032481A1 (en) 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
US6699880B1 (en) 1999-10-13 2004-03-02 Banyu Pharmaceutical Co., Ltd. Substituted imidazolidinone derivatives
SE9904652D0 (sv) * 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
EP1263754A1 (en) * 2000-02-01 2002-12-11 Millennium Pharmaceuticals, Inc. INDALONE AND BENZIMIDAZOLONE INHIBITORS OF FACTOR Xa
ES2340441T3 (es) * 2001-04-18 2010-06-02 Euro-Celtique S.A. Compuestos de octahidrobencimidazolona como analgesicos.
CA2444595A1 (en) * 2001-04-20 2002-10-31 Banyu Pharmaceutical Co., Ltd. Benzimidazolone derivatives
US6951849B2 (en) * 2001-10-02 2005-10-04 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
WO2004089942A2 (en) * 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
KR20040047877A (ko) * 2001-10-02 2004-06-05 아카디아 파마슈티칼스 인코포레이티드 무스카린 제제로서 벤즈이미다졸리디논 유도체
EP1451173A4 (en) * 2001-11-01 2005-10-26 Icagen Inc PIPERIDINE
ES2392340T3 (es) 2002-03-29 2012-12-07 Mitsubishi Tanabe Pharma Corporation Remedio para los trastornos del sueño
AU2003245565B2 (en) 2002-06-17 2008-01-03 Banyu Pharmaceutical Co., Ltd. Ophthalmic compositions for treating ocular hypertension
CA2509711A1 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Piperidine derivatives as ccr5 antagonists
JP2005102133A (ja) 2003-04-28 2005-04-14 Ricoh Co Ltd 画像形成装置及び宛先情報参照方法
JP2006528186A (ja) * 2003-07-23 2006-12-14 ワイス ５−ヒドロキシトリプタミン−６リガンドとしてのスルホニルジヒドロベンゾイミダゾロン化合物
GEP20084527B (en) * 2003-09-03 2008-11-10 Pfizer Benzimidazolone compounds having 5-ht4 receptor agonistic activity
EP1809607B1 (en) * 2004-11-02 2008-12-17 Pfizer, Inc. Sulfonyl benzimidazole derivatives
US7300947B2 (en) * 2005-07-13 2007-11-27 Banyu Pharmaceutical Co., Ltd. N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives
JP5209479B2 (ja) 2005-09-30 2013-06-12 グラクソ グループ リミテッド Ｍ１受容体にて活性を有するベンゾイミダゾロン類
JP5209480B2 (ja) 2005-09-30 2013-06-12 グラクソ グループ リミテッド Ｍ１受容体にて活性を有する化合物および医薬におけるそれらの使用
JP5209481B2 (ja) 2005-09-30 2013-06-12 グラクソ グループ リミテッド Ｍ１受容体にて活性を有する化合物および医薬におけるそれらの使用
BRPI0716602A2 (pt) 2006-09-08 2013-09-17 Gillette Co escova de dentes com méltiplos estados de cerda
GB0706168D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706187D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706189D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706165D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706188D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706190D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706170D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706167D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706173D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706164D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706174D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
NZ566508A (en) 2011-07-29
BRPI0616609A2 (pt) 2011-06-28
EP1943230A2 (en) 2008-07-16
CA2624504A1 (en) 2007-04-05
IL190219A0 (en) 2008-11-03
MY148504A (en) 2013-04-30
US8481566B2 (en) 2013-07-09
JO2634B1 (en) 2012-06-17
WO2007036715A2 (en) 2007-04-05
JP5209480B2 (ja) 2013-06-12
AR056103A1 (es) 2007-09-19
UA101299C2 (uk) 2013-03-25
ATE492537T1 (de) 2011-01-15
US20080255195A1 (en) 2008-10-16
NO20081945L (no) 2008-06-04
CR9904A (es) 2008-07-29
EP1943230B1 (en) 2010-12-22
TW200806657A (en) 2008-02-01
AU2006296369B2 (en) 2012-12-20
TWI389905B (zh) 2013-03-21
WO2007036715A3 (en) 2007-05-18
AU2006296369A1 (en) 2007-04-05
EA016286B1 (ru) 2012-03-30
US20080058378A1 (en) 2008-03-06
IL190219A (en) 2012-10-31
EA200801001A1 (ru) 2008-08-29
KR20080049090A (ko) 2008-06-03
KR20130091791A (ko) 2013-08-19
US8283364B2 (en) 2012-10-09
PE20070490A1 (es) 2007-05-30
CA2624504C (en) 2014-07-08
CN101321736B (zh) 2012-04-04
ZA200802167B (en) 2009-08-26
MA29849B1 (fr) 2008-10-03
JP2009512635A (ja) 2009-03-26
KR101374458B1 (ko) 2014-03-17
CN101321736A (zh) 2008-12-10

Similar Documents

Publication Publication Date Title
DE602006019119D1 (de) Verbindungen mit aktivität am m1-rezeptor und ihre verwendung in der medizin
DE602005023681D1 (de) Infrarotabsorbierende Verbindungen und deren Verwendung in Bildaufzeichnungselementen
DE602006007921D1 (de) Sensor und Aufzeichnungsgerät mit demselben
ATE468326T1 (de) Verbindungen zur verstärkung der glutamatrezeptorwirkung und deren verwendung in der medizin
ATE381335T1 (de) 2-cyanopyrrolopyrimidine und deren pharmazeutische verwendung
ATE530553T1 (de) Zytotoxische mittel mit neuen tomamycin-derivaten und ihre therapeutische verwendung
DE602006017566D1 (de) Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
ATE473229T1 (de) Tricyclische verbindungen und deren verwendung als mglur1-antagonisten
DE602006007049D1 (de) Heizelement und Heizvorrichtung mit Heizelementen
EP1746902A4 (en) MULTI-LECTIN AFFINITY CHROMATOGRAPHY AND USES THEREOF
EP2037917A4 (en) Pharmaceutical composition comprising amlodipine and losartan
ATE479437T1 (de) Benzoä4,5üthienoä2,3-düpyrimidin-4-one und ihre therapeutische verwendung
DE602005022169D1 (de) Polymerisierbare verbindungen und verwendung davon
EP1919288A4 (en) MEDICAMENTS CONTAINING FAMOTIDINE AND IBUPROFEN, AND ADMINISTRATION OF SAID DRUGS
EP1876178A4 (en) CYANOPYRIDINE DERIVATIVE AND THE USE THEREOF AS A MEDICAMENT
ATE428710T1 (de) Substituierte phenylaminothiazole und ihre verwendung
DE602005007546D1 (de) Kombiniertes Screening-System mit Röntgenstrahlendiffraktion und Ramanspektroskopie
DE602004003030D1 (de) Infrarot-absorbierende verbindungen und ihre verwendung in bebilderbaren elementen
ATE417045T1 (de) Substituierte diazaspiroä5.5üundecanderivate und deren verwendung als neurokininantagonisten
EP1937057A4 (en) CULTIVAR OF RICE CALLED "CL131"
ATE485023T1 (de) Saugfähiger einwegartikel mit entfaltbarem gurtband
ATE511507T1 (de) Piperidinylcarbonylpyrrolidine und deren verwendung als melanocortinagonisten
EP2098513A4 (en) TRICYCLIC COMPOUND AND ITS PHARMACEUTICAL USE
ATE555097T1 (de) 4-cycloalkyl-substituierte tetrahydrochinolinderivate und deren verwendung als medikamente
EP1912921A4 (en) TETRAAZAPORPHYRIN COMPOUNDS AND USES THEREOF